ClinicalTrials.gg
RecruitingNCT05433441ES-ParkUpdated Jul 23, 2025

Evaluation of the Effectiveness of the Parkinson Specialized Teams Intervention

An interventional study of ESPark Intervention in Parkinson Disease, sponsored by University Hospital, Bordeaux. Recruiting at 4 sites in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-23.

Sponsored by University Hospital, Bordeaux · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Dec 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Parkinson Disease by University Hospital, Bordeaux — 4 open to participants now, 4 under way, none of them phase 3. Parkinson Disease · University Hospital, Bordeaux.

Planned enrollment
Largest of 12
250 · median 31
Started
2022
the only one that year
No phase
12 of 14
3 open now
Registered
10th of 14
by date

Among the 14 studies in Parkinson Disease by University Hospital, Bordeaux, this one has the largest planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2022, is one of 12 with no phase, and was the 10th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

4 of the 14 studies in Parkinson Disease by University Hospital, Bordeaux are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Parkinson Disease by University Hospital, Bordeaux, or all of them as a file.
02

Study summary

A pilot experiment interventional study is proposed in order to set up multidisciplinary team for Parkinson's patients at home. The aim of this study is to evaluate the effectiveness of this specialized Parkinson's team (ESPark) intervention a on the quality of life of patients with moderate to severe Parkinson's disease

Read the detailed description

Parkinson's disease (PD) and related disorders are the second most common cause of motor disability in the elderly after stroke. Progressively, the disability impacts the activities of daily living and social life of Parkinson's patients with a major impact on their quality of life. The diversity and complexity of the needs of parkinsonian patients and their caregivers justify a specific multidisciplinary approach. Several studies have evaluated the effectiveness of the intervention of such teams on the maintenance of activities of daily living and quality of life of Parkinson's patients with contradictory results. In France, the experience of specialized Alzheimer teams (ESA) based on the same concept seems to have brought positive results on autonomy and resocialization. Based on the positive experience of ESA intervention in Alzheimer's disease and in view of the data in the literature on Parkinson's disease, we would like to develop the same type of care with teams adapted to the problems of Parkinson's disease patients, which we could call ESParks, and to evaluate the effectiveness of such teams in the context of support for Parkinson's patients.

03

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • Parkinson
  • Quality of life
  • Complementary non drug intervention
  • Multidisciplinary approach
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For the patient:

  • Patient with a diagnosis of idiopathic Parkinson's disease
  • Patient over 18 years ;
  • Patient with a Hoehn and Yahr Stage greater than or equal to 3;
  • Patient without major cognitive impairment defined by a MOCA score ≥21
  • Patient living at home ;
  • Patient with an identified non-professional primary caregiver;
  • Person affiliated with or benefiting from a social security plan;
  • Free, informed and and express consent (confirmed in writing) (no later than the day of inclusion and before any examination required by the research).

For the caregiver:

  • Male or female over 18 years
  • Able to respond to research interviews/questionnaires
  • Free, informed and express consent (confirmed in writing) (no later than the day of inclusion and before any examination required by the research).

Exclusion criteria

Exclusion Criteria:

For the patient:

  • Patient with medically indicated dementia impairing comprehension and adherence, and/or with severe confusion or psycho-hallucinatory state;
  • Institutionalized or foster care patients;
  • Patients with a known severe and unstable general pathology that does not allow for patient follow-up;
  • Patients already included in another non-drug management trial;
  • Patients whose institutionalization is envisaged in the short term (within 6 months) or for whom a change of residence is envisaged in the short term and would not allow for follow-up assessments;
  • Patients under guardianship or unable to express consent
  • Primary caregiver not wishing to participate in the study or unable to be available for the planned study follow-up;
  • Presence of a primary caregiver with a known severe and unstable disease that does not allow for the conduct of the study;
  • Presence of a primary caregiver with a known cognitive or psychiatric disorder (chronic progressive psychosis) that does not allow for the proper conduct of the study.
  • Pregnant or breastfeeding woman.

For the caregiver:

  • Unable to follow the research interviews or questionnaires.
  • Primary caregiver not wishing to participate in the study or unable to be available for the planned study follow-up;
  • Primary caregiver with a known severe and unstable illness that does not allow for the proper conduct of the study;
  • Primary caregiver with known cognitive or psychiatric disorders (chronic progressive psychosis) that do not allow the study to be conducted properly.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • No intervention
    Standard care
  • Experimental
    ESPark Intervention

    Under medical prescription and in addition to medical and physiotherapy care, the ESPark will intervene in an ecological way with Parkinson's patients in order to rehabilitate them, maintain their autonomy in their daily life and their social life with the aim of improving the quality of life of the patient and his main caregiver. Beyond a rehabilitative intervention in the home, the ESPark's mission would also be to optimize the patient's living environment and possibly help with the implementation of the necessary aids in the continuity of medical care.

    Procedure: ESPark Intervention

Interventions

  • ProcedureESPark Intervention

    The treatment will include 15 sessions (1 session per week). An initial assessment will be carried out during the first session in order to determine the objectives and the personalized follow-up.

06

What researchers measure

Primary outcomes

  1. Score of quality of life scale (PDQ 39)

    Self-questionnaire in 39 items evaluating the quality of life of Parkinson's patients from a motor and psychological point of view. Each question is rated from 0 (no disturbance) to 4 (maximum disturbance). The items are divided into 8 dimensions (activity of daily living, emotional well-being, psychological discomfort, social support, cognitive impairment, communication, physical discomfort, mobility) It consists of 39 items with a total score that varies from 0 to 154

    Time frame: Initial Visit - Day 0

  2. Score of quality of life scale (PDQ 39)

    Self-questionnaire in 39 items evaluating the quality of life of Parkinson's patients from a motor and psychological point of view. Each question is rated from 0 (no disturbance) to 4 (maximum disturbance). The items are divided into 8 dimensions (activity of daily living, emotional well-being, psychological discomfort, social support, cognitive impairment, communication, physical discomfort, mobility) It consists of 39 items with a total score that varies from 0 to 154

    Time frame: 6 months

Secondary outcomes

  1. IADL assessment

    Assessment of the level of dependence in instrumental activities of daily living It consists of 9 items with a total score that varies from 0 to 36 Each item is scored from 0 (autonom) to 4 (no autonom) or NA

    Time frame: Initial Visit - Day 0

  2. IADL assessment

    Assessment of the level of dependence in instrumental activities of daily living

    Time frame: 6 months

  3. IADL assessment

    Assessment of the level of dependence in instrumental activities of daily living

    Time frame: 12 months

  4. Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Rate

    Used to evaluate the various motor and non-motor symptoms. In this protocol, only motor examination will be carried out. This part includes the following items: speech, facial expression, rigidity, finger tapping, hand movements, hand pronation supination movements, toe tapping, leg agility, getting up from the examination chair, walking, postural stability, posture, overall spontaneity of movement, postural hand tremor, hand action tremor, amplitude of resting tremor, constancy of resting tremor. The items of the Parkinsonian triad are evaluated on the different parts of the body (extremities of the limbs, lip and jaw for resting tremor and neck for rigidity). The presence of dyskinesias is mentioned at the end of the evaluation and if they interfered with the motor examination, as well as the global scale of Hoehn and Yahr. All items are rated from 0 to 4 and are clearly defined : 0: normal, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe

    Time frame: Initial Visit - Day 0

  5. Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Rate

    Used to evaluate the various motor and non-motor symptoms. In this protocol, only motor examination will be carried out. This part includes the following items: speech, facial expression, rigidity, finger tapping, hand movements, hand pronation supination movements, toe tapping, leg agility, getting up from the examination chair, walking, postural stability, posture, overall spontaneity of movement, postural hand tremor, hand action tremor, amplitude of resting tremor, constancy of resting tremor. The items of the Parkinsonian triad are evaluated on the different parts of the body (extremities of the limbs, lip and jaw for resting tremor and neck for rigidity). The presence of dyskinesias is mentioned at the end of the evaluation and if they interfered with the motor examination, as well as the global scale of Hoehn and Yahr. All items are rated from 0 to 4 and are clearly defined : 0: normal, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe

    Time frame: 6 months

  6. Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Rate

    Used to evaluate the various motor and non-motor symptoms. In this protocol, only motor examination will be carried out. This part includes the following items: speech, facial expression, rigidity, finger tapping, hand movements, hand pronation supination movements, toe tapping, leg agility, getting up from the examination chair, walking, postural stability, posture, overall spontaneity of movement, postural hand tremor, hand action tremor, amplitude of resting tremor, constancy of resting tremor. The items of the Parkinsonian triad are evaluated on the different parts of the body (extremities of the limbs, lip and jaw for resting tremor and neck for rigidity). The presence of dyskinesias is mentioned at the end of the evaluation and if they interfered with the motor examination, as well as the global scale of Hoehn and Yahr. All items are rated from 0 to 4 and are clearly defined : 0: normal, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe

    Time frame: 12 months

  7. Non-motor symptoms Scale for Parkinson's Disease (NMSS)

    30-item scale that assesses a wide range of non-motor symptoms in patients with Parkinson's disease (PD). The NMSS measures the severity and frequency of non-motor symptoms across nine dimensions. The scale can be used for patients in all stages of PD.

    Time frame: Initial Visit - Day 0

  8. Non-motor symptoms Scale for Parkinson's Disease (NMSS)

    30-item scale that assesses a wide range of non-motor symptoms in patients with Parkinson's disease (PD). The NMSS measures the severity and frequency of non-motor symptoms across nine dimensions. The scale can be used for patients in all stages of PD.

    Time frame: 6 months

  9. Non-motor symptoms Scale for Parkinson's Disease (NMSS) score

    30-item scale that assesses a wide range of non-motor symptoms in patients with Parkinson's disease (PD). The NMSS measures the severity and frequency of non-motor symptoms across nine dimensions. The scale can be used for patients in all stages of PD.

    Time frame: 12 months

  10. Montreal Cognitive Assessment (MOCA) score

    The MoCA assesses mild cognitive dysfunction. It assesses the following functions: short-term memory, visual-spatial skills, executive functions, attention, concentration, working memory, language, abstraction, calculation and orientation in time and space. Cognitive impairment is assessed using a 30-point score (27-30: no cognitive impairment; 18-26: mild; 10-17: moderate; \< 10: severe).

    Time frame: Initial Visit - Day 0

  11. Montreal Cognitive Assessment (MOCA) score

    The MoCA assesses mild cognitive dysfunction. It assesses the following functions: short-term memory, visual-spatial skills, executive functions, attention, concentration, working memory, language, abstraction, calculation and orientation in time and space. Cognitive impairment is assessed using a 30-point score (27-30: no cognitive impairment; 18-26: mild; 10-17: moderate; \< 10: severe).

    Time frame: 6 months

  12. Montreal Cognitive Assessment (MOCA) score

    The MoCA assesses mild cognitive dysfunction. It assesses the following functions: short-term memory, visual-spatial skills, executive functions, attention, concentration, working memory, language, abstraction, calculation and orientation in time and space. Cognitive impairment is assessed using a 30-point score (27-30: no cognitive impairment; 18-26: mild; 10-17: moderate; \< 10: severe).

    Time frame: 12 months

  13. Beck Depression Inventory (BDI-II) score

    Self-questionnaire comprising a list of 21 items measuring the somatic, affective and cognitive severity of depressive symptoms. Each item is rated for symptom severity and/or frequency, over the past 7 days, on a 4-point scale ranging from 0 to 3. Higher scores indicate severe symptomatology.

    Time frame: Initial Visit - Day 0

  14. Beck Depression Inventory (BDI-II) score

    Self-questionnaire comprising a list of 21 items measuring the somatic, affective and cognitive severity of depressive symptoms. Each item is rated for symptom severity and/or frequency, over the past 7 days, on a 4-point scale ranging from 0 to 3. Higher scores indicate severe symptomatology.

    Time frame: 6 months

  15. Beck Depression Inventory (BDI-II) score

    Self-questionnaire comprising a list of 21 items measuring the somatic, affective and cognitive severity of depressive symptoms. Each item is rated for symptom severity and/or frequency, over the past 7 days, on a 4-point scale ranging from 0 to 3. Higher scores indicate severe symptomatology.

    Time frame: 12 months

  16. Parkinson Anxiety Scale (PAS) Score

    Self-questionnaire assessing anxiety in Parkinson's disease dealing with several dimensions of anxiety: Persistent anxiety (5 items), Episodic anxiety (4 items), Avoidance behavior (3 items). Each item is scored from 0 (not at all) to 4 (strongly or almost always).

    Time frame: Initial Visit - Day 0

  17. Parkinson Anxiety Scale (PAS) Score

    Self-questionnaire assessing anxiety in Parkinson's disease dealing with several dimensions of anxiety: Persistent anxiety (5 items), Episodic anxiety (4 items), Avoidance behavior (3 items). Each item is scored from 0 (not at all) to 4 (strongly or almost always).

    Time frame: 6 months

  18. Parkinson Anxiety Scale (PAS) Score

    Self-questionnaire assessing anxiety in Parkinson's disease dealing with several dimensions of anxiety: Persistent anxiety (5 items), Episodic anxiety (4 items), Avoidance behavior (3 items). Each item is scored from 0 (not at all) to 4 (strongly or almost always).

    Time frame: 12 months

  19. Reduced Neuropsychiatric Inventory (NPI-R) score

    Used to assesses 12 domains of psychobehavioral disorders (21). It is a questionnaire consisting of a screening question and seven to nine items for each of the 12 domains: delusions, hallucinations, agitation/aggressiveness, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, motor aberration, behavioural disorders, sleep, appetite and eating. The score ranges from 0 to 144 .

    Time frame: Initial Visit - Day 0

  20. Reduced Neuropsychiatric Inventory (NPI-R) score

    Used to assesses 12 domains of psychobehavioral disorders (21). It is a questionnaire consisting of a screening question and seven to nine items for each of the 12 domains: delusions, hallucinations, agitation/aggressiveness, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, motor aberration, behavioural disorders, sleep, appetite and eating. The score ranges from 0 to 144 .

    Time frame: 6 months

  21. Reduced Neuropsychiatric Inventory (NPI-R) score

    Used to assesses 12 domains of psychobehavioral disorders. It is a questionnaire consisting of a screening question and seven to nine items for each of the 12 domains: delusions, hallucinations, agitation/aggressiveness, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, motor aberration, behavioural disorders, sleep, appetite and eating. The score ranges from 0 to 144 .

    Time frame: 12 months

  22. Zarit scale score

    This scale assesses caregiver burden ; it consists of 22 items with a total score that varies from 0 to 88. (score ≤20, no burden - score\> 60, severe burden).

    Time frame: Initial Visit - Day 0

  23. Zarit scale score

    This scale assesses caregiver burden ; it consists of 22 items with a total score that varies from 0 to 88. (score ≤20, no burden - score\> 60, severe burden).

    Time frame: 6 Months

  24. Zarit scale score

    This scale assesses caregiver burden ; it consists of 22 items with a total score that varies from 0 to 88. (score ≤20, no burden - score\> 60, severe burden).

    Time frame: 12 Months

  25. State Trait Anxiety Inventory short scale (STAI-E and STAI-T) score

    This anxiety scale consists of 2 scales of 20 questions that assess how subjects feel at the time and generally.

    Time frame: Initial Visit - Day 0

  26. State Trait Anxiety Inventory short scale (STAI-E and STAI-T) score

    This anxiety scale consists of 2 scales of 20 questions that assess how subjects feel at the time and generally.

    Time frame: 6 months

  27. State Trait Anxiety Inventory short scale (STAI-E and STAI-T) score

    This anxiety scale consists of 2 scales of 20 questions that assess how subjects feel at the time and generally.

    Time frame: 12 months

  28. Quality of life as measured by the PQoL Carers.

    Quality of life questionnaire for caregivers Self-questionnaire comprising a list of 26 items with a total score that varies from 0 to 104

    Time frame: Initial Visit - Day 0

  29. Quality of life as measured by the PQoL Carers.

    Quality of life questionnaire for caregivers Self-questionnaire comprising a list of 26 items with a total score that varies from 0 to 104

    Time frame: 6 months

  30. Quality of life as measured by the PQoL Carers.

    Quality of life questionnaire for caregivers Self-questionnaire comprising a list of 26 items with a total score that varies from 0 to 104

    Time frame: 12 months

  31. Sense of competence questionnaire

    This 35-item questionnaire covers three areas: the impact of caregiving on the caregiver's personal life, satisfaction with one's own performance as a caregiver, and satisfaction with the person with dementia as a recipient of care Each item is scored from 1 ("yes") to 3 ("No") and 2 (Yes/no) The total score varies from 27 to 81

    Time frame: Initial Visit - Day 0

  32. Sense of competence questionnaire

    This 35-item questionnaire covers three areas: the impact of caregiving on the caregiver's personal life, satisfaction with one's own performance as a caregiver, and satisfaction with the person with dementia as a recipient of care Each item is scored from 1 ("yes") to 3 ("No") and 2 (Yes/no) The total score varies from 27 to 81

    Time frame: 6 months

  33. Sense of competence questionnaire

    This 35-item questionnaire covers three areas: the impact of caregiving on the caregiver's personal life, satisfaction with one's own performance as a caregiver, and satisfaction with the person with dementia as a recipient of care Each item is scored from 1 ("yes") to 3 ("No") and 2 (Yes/no) The total score varies from 27 to 81

    Time frame: 12 months

  34. Ressource Utilization in Dementia (RUD)

    The questionnaire allows us to estimate the medico-social costs associated with the care of the patient. This estimate is based on the evaluation of the quantity of formal resources (including social services, home care) and informal resources (care and assistance provided by the caregiver) involved in the day-to-day care of the patient; the resources are valued economically using the health insurance rates, where applicable, and the hourly costs of medical and social assistance at home

    Time frame: Initial Visit - Day 0

  35. Ressource Utilization in Dementia (RUD)

    The questionnaire allows us to estimate the medico-social costs associated with the care of the patient. This estimate is based on the evaluation of the quantity of formal resources (including social services, home care) and informal resources (care and assistance provided by the caregiver) involved in the day-to-day care of the patient; the resources are valued economically using the health insurance rates, where applicable, and the hourly costs of medical and social assistance at home

    Time frame: 6 Months

  36. Ressource Utilization in Dementia (RUD)

    The questionnaire allows us to estimate the medico-social costs associated with the care of the patient. This estimate is based on the evaluation of the quantity of formal resources (including social services, home care) and informal resources (care and assistance provided by the caregiver) involved in the day-to-day care of the patient; the resources are valued economically using the health insurance rates, where applicable, and the hourly costs of medical and social assistance at home

    Time frame: 12 Months

07

Study locations

4 of 4 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Dec 2025, 36 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 36 months is above that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2022
First posted
Jun 27, 2022
StartActual
Dec 6, 2022
Primary completionEst.
Dec 6, 2025
CompletionEst.
Jun 6, 2027
Last update
Jul 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05433441
Responsible party
Sponsor
First posted
Jun 27, 2022
Start date
Dec 6, 2022
Primary completion
Dec 6, 2025 (estimated)
Completion
Jun 6, 2027 (estimated)
Last update
Jul 23, 2025

Study contacts

Alexandra FOUBERT-SAMIER, Dr
Contact
alexandra.samier-foubert@u-bordeaux.fr
05 57 82 12 53
Sandrine DUPOUY
Contact
sandrine.dupouy@chu-bordeaux.fr
05 57 82 14 62
Alexandra FOUBERT-SAMIER
principal investigator · University Hospital, Bordeaux

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion